These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30049300)

  • 1. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized anemia management reduces hemoglobin variability in hemodialysis patients.
    Gaweda AE; Aronoff GR; Jacobs AA; Rai SN; Brier ME
    J Am Soc Nephrol; 2014 Jan; 25(1):159-66. PubMed ID: 24029429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of model predictive control for improved anemia management.
    Brier ME; Gaweda AE; Dailey A; Aronoff GR; Jacobs AA
    Clin J Am Soc Nephrol; 2010 May; 5(5):814-20. PubMed ID: 20185598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis.
    Khan I; Krishnan M; Kothawala A; Ashfaq A
    BMC Nephrol; 2011 May; 12():22. PubMed ID: 21595975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model predictive control of erythropoietin administration in the anemia of ESRD.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
    Spiegel DM; Khan I; Krishnan M; Mayne TJ
    Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study.
    Bae SY; Jeon JW; Kim SH; Baek CH; Jang JW; Yang WS; Kim SB; Park SK; Lee SK; Kim H
    BMC Nephrol; 2019 Aug; 20(1):295. PubMed ID: 31375077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
    Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.
    Aapro M; Ludwig H; Bokemeyer C; MacDonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Ann Oncol; 2009 Oct; 20(10):1714-21. PubMed ID: 19570966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining optimum hemoglobin sampling for anemia management from every-treatment data.
    Gaweda AE; Nathanson BH; Jacobs AA; Aronoff GR; Germain MJ; Brier ME
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1939-45. PubMed ID: 20671221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.